OneMedNet Corp — Director's Dealing 2025

Nov 27, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OneMedNet Corp (ONMD)
CIK: 0001849380
Period of Report: 2024-01-19

Reporting Person: Kosasa Thomas (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-01-19	Common Stock	A	45000	$0.00	Acquired	8378824	Direct
2025-04-21	Common Stock	P	47000	$0.4864	Acquired	8425824	Direct
2025-06-16	Common Stock	P	55000	$0.3821	Acquired	8480824	Direct
2025-06-17	Common Stock	C	493056	$1.14	Acquired	8973880	Direct
2025-06-19	Common Stock	C	2123424	$0.753	Acquired	11097304	Direct
2025-06-19	Common Stock	C	2865016	$0.71	Acquired	13962320	Direct
2025-06-20	Common Stock	P	1190476	$0.42	Acquired	15152796	Direct
2025-08-29	Common Stock	P	581395	$0.86	Acquired	15734191	Direct
2025-09-24	Common Stock	P	6000	$0.9331	Acquired	15740191	Direct
2025-11-26	Common Stock	A	45000	$0.00	Acquired	15785191	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-06-17	Senior Secured Convertible Note	$1.14	C	493056	Disposed		Common Stock (493056)	Direct

Footnotes

F1: Represents restricted stock units ("RSUs") granted as director compensation under the OneMedNet Corporation 2022 Equity Incentive Plan (the "2022 Plan") for board service in fiscal year 2024. Each RSU represents the contingent right to receive one share of the issuer's common stock. The RSUs vested on December 31, 2024.

F2: On June 28, 2023, Data Knights Acquisition Corp. ("Data Knights") (the predecessor of the issuer) and certain investors, including the reporting person (collectively, the "Purchasers"), entered into a securities purchase agreement pursuant to which Data Knights issued and sold to the Purchasers senior secured convertible notes (the "PIPE Notes"), which are convertible into shares of common stock at each Purchasers' election, at a conversion price equal to the lower of (i) $10.00 per share, or (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) trading days immediately preceding the conversion date, subject to a floor price of $1.14. The PIPE Notes matured on the first anniversary of the issuance date (November 7, 2024), subject to extension pursuant to the terms of the PIPE Notes. The conversion shares included accrued interest from the date of issuance.

F3: On June 19, 2025, the reporting person delivered notice of his election to convert in full the amounts of outstanding principal under certain convertible shareholder loans previously made by the reporting person to the issuer, in an aggregate principal amount of approximately $1.6 million.

F4: On June 19, 2025, the issuer entered into an agreement with the reporting person to convert an aggregate of approximately $2.0 million of outstanding principal and accrued interest under certain shareholder loans and business combination extension loans.

F5: On June 20, 2025, the issuer entered into a subscription agreement with the reporting person, pursuant which the issuer agreed to sell 1,190,476 shares of common stock to the reporting person at a purchase price of $0.42 per share, totaling $500,000 in gross proceeds to the issuer.

F6: On August 29, 2025, the issuer entered into a subscription agreement with the reporting person, pursuant to which the issuer agreed to sell 581,395 shares of common stock to the reporting person at a purchase price of $0.86 per share, totaling $500,000 in gross proceeds to the issuer.

F7: Represents RSUs granted as director compensation under the 2022 Plan for board service in fiscal year 2025. The RSUs vest on December 31, 2025, subject to the reporting person's continued service with the issuer through the vesting date.